668 related articles for article (PubMed ID: 29702142)
1. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
3. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
4. Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses.
Julier Z; de Titta A; Grimm AJ; Simeoni E; Swartz MA; Hubbell JA
Vaccine; 2016 May; 34(21):2453-2459. PubMed ID: 27016652
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.
Zhu M; Ding X; Zhao R; Liu X; Shen H; Cai C; Ferrari M; Wang HY; Wang RF
J Control Release; 2018 Feb; 272():72-82. PubMed ID: 29325699
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
Jin JW; Tang SQ; Rong MZ; Zhang MQ
Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
[TBL] [Abstract][Full Text] [Related]
7. Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction.
Zhao Z; Harris B; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C
Biomaterials; 2018 Feb; 155():165-175. PubMed ID: 29179132
[TBL] [Abstract][Full Text] [Related]
8. Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells.
Coelho-Dos-Reis JG; Huang J; Tsao T; Pereira FV; Funakoshi R; Nakajima H; Sugiyama H; Tsuji M
Clin Immunol; 2016 Jul; 168():6-15. PubMed ID: 27132023
[TBL] [Abstract][Full Text] [Related]
9. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
Ilyinskii PO; Roy CJ; O'Neil CP; Browning EA; Pittet LA; Altreuter DH; Alexis F; Tonti E; Shi J; Basto PA; Iannacone M; Radovic-Moreno AF; Langer RS; Farokhzad OC; von Andrian UH; Johnston LP; Kishimoto TK
Vaccine; 2014 May; 32(24):2882-95. PubMed ID: 24593999
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
12. Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays.
Inglefield J; Catania J; Harris A; Hickey T; Ma Z; Minang J; Baranji K; Spangler T; Look J; Ruiz C; Lu H; Alleva D; Reece JJ; Lacy MJ
Vaccine; 2022 Sep; 40(38):5544-5555. PubMed ID: 35773119
[TBL] [Abstract][Full Text] [Related]
13. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
[TBL] [Abstract][Full Text] [Related]
14. An allergen-fused dendritic cell-binding peptide enhances in vitro proliferation of equine T-cells and cytokine production.
Ziegler A; Olzhausen J; Hamza E; Stojiljkovic A; Stoffel MH; Garbani M; Rhyner C; Marti E
Vet Immunol Immunopathol; 2022 Jan; 243():110351. PubMed ID: 34800874
[TBL] [Abstract][Full Text] [Related]
15. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
16. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
17. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
Front Immunol; 2021; 12():803090. PubMed ID: 35003132
[TBL] [Abstract][Full Text] [Related]
18. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.
Zaks K; Jordan M; Guth A; Sellins K; Kedl R; Izzo A; Bosio C; Dow S
J Immunol; 2006 Jun; 176(12):7335-45. PubMed ID: 16751377
[TBL] [Abstract][Full Text] [Related]
19. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses.
Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Dolzhikova IV; Stanhope-Baker P; Naroditsky BS; Gudkov AV; Logunov DY; Gintsburg AL
PLoS One; 2016; 11(5):e0155650. PubMed ID: 27187797
[TBL] [Abstract][Full Text] [Related]
20. A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV.
Poteet E; Lewis P; Li F; Zhang S; Gu J; Chen C; Ho SO; Do T; Chiang S; Fujii G; Yao Q
PLoS One; 2015; 10(8):e0136862. PubMed ID: 26312747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]